On June 18, 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.


Find information on this page to support you with covering the news.

Media release

Investor webcast

An investor conference call and webcast will be held to discuss the Global Phase 3 program, the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan. The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers).

Date:         Monday June 18, 2018

Time:        14:00 CEST | 13:00 BST | 08:00 EDT

 

Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial-in:      CH: +41 (0)44 580 65 22 |  UK: +44 203 009 2470  |  US: +1 877 423 0830

PIN:           66706100#

 

Are you looking for information on cerebral vasospasm?

Are you looking for information on cerebral vasospasm?